Yuki Kinoshita

Yuki Kinoshita

Auto-generated profile, based on publicly available information

Yuki Kinoshita

Department of Dermatology, Osaka Metropolitan University Graduate School of Medicine , Osaka

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 October 2013 in Chemistry Letters
Verified
Journal Article
Closed access
HMHitoshi Mizuguchi
Hitoshi Mizuguchi
JSJun Sakurai
Jun Sakurai
YKYuki Kinoshita
Yuki Kinoshita
MIMasamitsu Iiyama
Masamitsu Iiyama
TKTatsuro Kijima
Tatsuro Kijima
JSJunichi Shida
Junichi Shida
The new type of amperometric biosensor described herein, which was fabricated by using a track-etched microporous membrane electrode for glucose detection, comprises a prereactor electrode, a detector electrode, and an immobilized enzyme reactor sandwiched between these electrodes. Because the sample solution flows through this system, the interferents are electrolyzed completely at the prereactor, positioned upstream of the enzyme reactor. The increased current response at the detector electrode derives solely from oxidation of hydrogen peroxide produced in the enzymatic reaction. Sensitive and selective response toward glucose detection was obtained with no other catalytic material such as peroxidase or an electron mediator.

16 January 2024 in Skin Health and Disease
Verified
Journal Article
Open access
YKYuki Kinoshita
Yuki Kinoshita
HIHisayoshi Imanishi
Hisayoshi Imanishi
TOTomoko Oshimo
Tomoko Oshimo
DTDaisuke Tsuruta
Daisuke Tsuruta
Dupilumab is a humanized monoclonal antibody against the interleukin (IL)-4 receptor alpha chain that inhibits IL-4 and IL-13 signalling. It is one of the systemic treatments for patients with moderate-to-severe atopic dermatitis (AD), which provides favourable safety and efficacy. We report a case of psoriasis-like eruption induced by dupilumab as an adverse effect in a patient with AD, immediately remitted after switching to baricitinib, which inhibits JAK1/2. Moreover, the atopic skin lesion also simultaneously went into remission upon baricitinib treatment. Baricitinib could be a favourable option for patients with AD who develop dupilumab-induced psoriasis-like eruption.

7 July 2022 in The Journal of Dermatology
Verified
Journal Article
Closed access
YKYuki Kinoshita
Yuki Kinoshita
CTChiharu Tateishi
Chiharu Tateishi
JSJunko Sowa‐Osako
Junko Sowa‐Osako
NKNao Kusutani
Nao Kusutani
MOMasahiko Ohsawa
Masahiko Ohsawa
DTDaisuke Tsuruta
Daisuke Tsuruta